Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The Influence of Bowel Preparation on ADC Measurements: Comparison between Conventional DWI and DWIBS Sequences.

Apine I, Baduna M, Pitura R, Pokrotnieks J, Krumina G.

Medicina (Kaunas). 2019 Jul 21;55(7). pii: E394. doi: 10.3390/medicina55070394.

2.

Gut Microbiota as a Host Defender and a Foe: The 2 Faces of Commensal Bacteroides thetaiotaomicron in Inflammatory Bowel Disease.

Sitkin S, Pokrotnieks J.

Inflamm Bowel Dis. 2019 May 4;25(6):e71. doi: 10.1093/ibd/izy377. No abstract available.

PMID:
30561647
3.

Clinical Potential of Anti-inflammatory Effects of Faecalibacterium prausnitzii and Butyrate in Inflammatory Bowel Disease.

Sitkin S, Pokrotnieks J.

Inflamm Bowel Dis. 2019 Mar 14;25(4):e40-e41. doi: 10.1093/ibd/izy258. No abstract available.

PMID:
30085080
4.

Alterations in Polyunsaturated Fatty Acid Metabolism and Reduced Serum Eicosadienoic Acid Level in Ulcerative Colitis: Is There a Place for Metabolomic Fatty Acid Biomarkers in IBD?

Sitkin S, Pokrotnieks J.

Dig Dis Sci. 2018 Sep;63(9):2480-2481. doi: 10.1007/s10620-018-5182-5. Epub 2018 Jul 9. No abstract available.

PMID:
29987625
5.

A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.

Pokrotnieks J, Sitkin S.

J Gastroenterol. 2018 Jun;53(6):799-800. doi: 10.1007/s00535-018-1458-y. Epub 2018 Apr 3. No abstract available.

PMID:
29616331
6.

How to Increase the Butyrate-producing Capacity of the Gut Microbiome: Do IBD Patients Really Need Butyrate Replacement and Butyrogenic Therapy?

Sitkin S, Vakhitov T, Pokrotnieks J.

J Crohns Colitis. 2018 Jun 28;12(7):881-882. doi: 10.1093/ecco-jcc/jjy033. No abstract available.

PMID:
29528388
7.

Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study.

Issa Y, van Santvoort HC, Fockens P, Besselink MG, Bollen TL, Bruno MJ, Boermeester MA; Collaborators.

HPB (Oxford). 2017 Nov;19(11):978-985. doi: 10.1016/j.hpb.2017.07.006. Epub 2017 Aug 15.

8.

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group.

J Crohns Colitis. 2014 Sep;8(9):970-80. doi: 10.1016/j.crohns.2014.01.021. Epub 2014 Feb 15.

9.

IBD prevalence in Baltic states or just a guessing game?

Krustins E, Pokrotnieks J.

J Crohns Colitis. 2014 Aug;8(8):902. doi: 10.1016/j.crohns.2014.01.015. Epub 2014 Jan 31. No abstract available.

PMID:
24491517
10.

Current opinion on the management of iron deficiency anaemia in gastrointestinal diseases.

Derovs A, Pokrotnieks J, Derova J, Danilans A, Pukitis A, Dombure P, Leiniece S, Zeltina Indra.

Eksp Klin Gastroenterol. 2014;(10):97-105.

PMID:
25911939
11.

European evidence based consensus for endoscopy in inflammatory bowel disease.

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation.

J Crohns Colitis. 2013 Dec;7(12):982-1018. doi: 10.1016/j.crohns.2013.09.016. Epub 2013 Nov 1. No abstract available.

12.

Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature.

Pukitis A, Zake T, Groma V, Ostrovskis E, Skuja S, Pokrotnieks J.

J Gastrointestin Liver Dis. 2013 Sep;22(3):333-6. Review.

13.

Regulatory evaluation of Glybera in Europe - two committees, one mission.

Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I, Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK.

Nat Rev Drug Discov. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. Epub 2013 Aug 19. No abstract available.

PMID:
23954897
14.

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.

Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group.

Gut. 2009 Feb;58(2):233-40. doi: 10.1136/gut.2008.154302. Epub 2008 Oct 2.

15.

Association of genetic variants with pancreatic cancer.

Skudra S, Stāka A, Puķītis A, Siņicka O, Pokrotnieks J, Nikitina M, Tracums J, Tihomirova L.

Cancer Genet Cytogenet. 2007 Nov;179(1):76-8. No abstract available.

PMID:
17981219

Supplemental Content

Loading ...
Support Center